Findings that acute hyperglycaemia activates PKC to cause negative effects on cardiomyocyte function, may go in some part to explain this loss of efficacy in clinical trials compared to in vitro and in vivo animal model studies. This evidence concerns the gene PRRT2 and Hyperglycemia.